Clinical efficacy of Patients With relapsed Acute myeloid leukaemia after Allogeneic hematopoietic c

来源 :第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 | 被引量 : 0次 | 上传用户：fangming286

【摘要】

：

【作者】

：

Dan hong Wang Guoliang Ding Liangding Hu Min Jiang Bin Zhang Hongmei Ning Yuhang Li Chen Xu Xiao Lou Jinchao Zhang Hu Chen

【机构】

：

Department of Hematopoietic Stem Cell Transplantation, Affiliated Hospital of Academy of Military Me

【出处】

：

第十八届全国临床肿瘤学大会暨2015年CSCO学术年会

【发表日期】

：

2015年4期

【关键词】

：

Acute myeloid leukaemia Allogeneic hematopoietic c

下载到本地 , 更方便阅读

下载此文赞助VIP

声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架

论文部分内容阅读

　　Objective: Acute myeloid leukemia (AML)relapse after allogeneic hematopoietic cell transplantation (allo-HSCT) remainsa major therapeutic challenge.DC vaccination andadoptive CIK cell transfer, provided proof-of-principle in trials with respectto therapeutic immunity being elicited leading to clinical responses.

其他文献

Immunotherapy with patient-specific antigens selection reduced the metastasis of acervical cancer pa

Objective: Cervical cancer is the second most common Gynecologic malignant tumor and frequently occurs in patients with human papilloma virus (HPV)infection.Effective treatment for cervical cancer (in

会议

MASCTCervical cancerTumor antigensspecific T cell

CRABP2 gene reverse platinum resistance via Fas signaling pathway in epithelial ovarian cancer

Objective: Platinum-resistant play an important role of poor prognosis in ovarian cancer.Cellular retinoic acid-binding protein 2(CRABP2) were considered the potential upstream molecules for inhibitin

会议

Platinum resistantEpithelial ovarian cancer

Irreversible electroporation mediated HPV18 E6 targeted shRNA suppressed cervical cancer growth in v

Objective: To verify the feasibility of using irreversible electroporation (IRE) to mediate HPV18 E6 shRNA plasmid into cervical cancer cell HeLa in vitro and in vivo, and their co-effect on cell and

会议

Irreversible electroporationshRNA plasmid

The clinical observation of Bevacizumab combined chemotherapy to treat persistent and/or recurrent u

Objective: To observe the therapeutic effect of Bevacizumab (BEV) combined chemotherapy to treat persistent and/or recurrent uterine sarcomas.Method: From May 2006 to May 2014 clinical data from 4 per

会议

Uterine sarcomasBevacizumabCombined chemotherapy

不可逆性电穿孔对宫颈癌残留肿瘤生物学行为的影响

目的：以不可逆性电穿孔(Irreversible electroporation；IRE)不完全消融人宫颈癌荷瘤裸鼠模型，研究残留肿瘤的生物学行为变化，为进一步优化IRE肿瘤治疗策提供理论依据。

会议

不可逆性电穿孔宫颈癌小动物活体成像

无花果水提取液抗宫颈癌细胞增殖作用的初步研究

目的：探讨无花果水提取液(fig extract,FE)对宫颈癌细胞(Hella细胞)增殖的影响及其机制。方法：MTT法检测不同浓度无花果提取液对宫颈癌细胞增殖的影响,荧光显微镜观察细胞形态改变,流式细胞术检测细胞凋亡变化。

会议

无花果宫颈癌细胞细胞凋亡

RNAi介导的WFDC2基因沉默在人卵巢浆液性上皮癌发展中的作用及其机制的初步研究

目的：1.构建WFDC2基因稳定低表达的人浆液性卵巢癌细胞株SKOV3,体外检测WFDC2基因沉默对肿瘤细胞增殖、凋亡、侵袭和迁移能力的影响.2.构建裸鼠皮下移植瘤模型,观察肿瘤生长、转移特点的变化.

会议

人附睾蛋白4卵巢癌

Weekly Carfilzomib With Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma: Upd

Objective: Carfilzomib (K) is a selective proteasome inhibitor that is approved in the United States for the treatment of relapsed and refractory multiple myeloma.

会议

CarfilzomibMultiple myeloma

Carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in patients with relapsed mu

Objective: ENDEAVOR (NCT01568866) is comparing Kd with Vd in patients with RMM.The primary endpoint is PFS.Secondary endpoints include OS, ORR, peripheral neuropathy (PN) rate, and safety.

会议

CarfilzomibBortezomibMultiple myeloma

A proposal of a new staging system for extranodal natural killer T-cell lymphoma, nasal-type: a mult

Objective: Extranodal NK/T-cell lymphoma, nasal type (ENKL), is a rare and highly aggressive disease.The Ann Arbor staging system (ASS) failed to predict survival differences among different stages in

会议

ENKLNew staging system

Clinical efficacy of Patients With relapsed Acute myeloid leukaemia after Allogeneic hematopoietic c

与本文相关的学术论文